Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advances of Molecular Biology and Translational Aspects in CNS Tumors"
Deadline for manuscript submissions: closed (31 December 2019).
Interests: Brain tumors; HNSCC; immunobiology; drug testing; cell models; biomarkers
Interests: Brain tumors; invasion; angiogenesis; metabolism; immunobiology; liquid biopsy; cell and animal models; drug testing
Interests: Neuroscience; primary brain tumours; brain macrophages; neurovascular unit
About 30.9 % of all primary CNS tumors in the US are malignant. The most commonly occurring malignant tumor is glioblastoma (14.7% of all and 47.7% of malignant tumors), and the most common nonmalignant tumor is meningioma (37.1% of all and 53.1% of nonmalignant tumors), with an overall incidence of 23.03 per 100,000 (CBTRUS 2018). The occurrence of secondary, metastatic tumors is about four times more common (NCI). Current therapy includes varying combinations of surgery, radio-, and chemotherapy. The five-year survival rate following diagnosis of a malignant CNS tumor is 35% and 90.7% for nonmalignant CNS tumors (CTRUS), indicating an urgent need for more effective therapies for different types of CNS tumors even if they are benign, as well as a better understanding of the molecular determinants of therapy response and tumor biology.
This Special Issue shall cover results of studies using animal or cell culture models to investigate the molecular underpinnings and treatment approaches of different CNS tumor types, applying molecular biological methods. This issue will also publish reports on tissue samples of patient tumors, providing novel mechanistic insights into new aspects that may impact on the development of novel biomarkers and clinical therapy of CNS tumors. In addition, reviews about the current status of new therapy options in different CNS cancer types and prognostic and predictive biomarkers will be published.
Prof. Dr. Christel Herold-Mende
Prof. Dr. Katrin Lamszus
Prof. Dr. Rainer Glass
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- molecular determinants of CNS tumors
- novel biomarkers
- novel therapeutics and mechanistic insights in mode of action
- drug screens
- transcriptional profiles